Clinova, the British consumer healthcare company, has increased Covaflu production to 96 million respirators annually following a surge in demand from local councils, emergency services and NHS trusts across the UK, as the UK government recommends masks in enclosed spaces.
FFP2 masks create a protective barrier between front-line employees and the COVID-19 virus.
Clinova has also eceived orders for the Covaflu FFP2 respirators from UK-based companies as they plan for post-lockdown working to avoid the spread of the virus.
Covaflu respirator masks were first launched by Clinova in the UK in 2007, proving essential during the previous swine flu and avian flu pandemics. They were the first product designed by Clinova’s founders when the company launched, based on the statistical probability that a viral pandemic was a ‘when’ and not an ‘if’.
Clinova’s chief medical officer and general practitioner, Dr Tom Bracewell, said: “PPE is essential for our front-line workers to access during this pandemic. It’s also great that, as a UK-based business, we can play a part in helping the country cope with this pandemic and also help boost the local economy. We feel proud to think that we are helping to protect firemen, paramedics, doctors, nurses, the police and the public.
“As a healthcare company, we have been doing everything we can to help the country get through COVID-19, as we have also added a Pandemic Flu section in our Caidr app with detailed information on the signs and symptoms of COVID-19.”